Unveiling Undiscovered Gems in India This October 2024

Over the last 7 days, the Indian market has experienced a slight dip of 1.0%, yet it remains robust with a remarkable 39% increase over the past year and earnings projected to grow by 17% annually. In this dynamic environment, identifying stocks with strong fundamentals and growth potential can uncover hidden opportunities that may thrive even amid fluctuating conditions.

Top 10 Undiscovered Gems With Strong Fundamentals In India

Name	Debt To Equity	Revenue Growth	Earnings Growth	Health Rating
3B Blackbio Dx	0.38%	-0.88%	-1.47%	★★★★★★
Kokuyo Camlin	27.11%	23.20%	75.70%	★★★★★★
Knowledge Marine & Engineering Works	35.48%	42.61%	42.95%	★★★★★★
TechNVision Ventures	100.73%	20.37%	68.50%	★★★★★★
Gallantt Ispat	18.85%	37.56%	37.26%	★★★★★☆
Voith Paper Fabrics India	0.07%	10.95%	9.70%	★★★★★☆
Master Trust	37.05%	27.64%	41.99%	★★★★★☆
Indo Tech Transformers	2.30%	22.05%	60.31%	★★★★★☆
Avantel	5.92%	33.97%	37.33%	★★★★★☆
Share India Securities	24.23%	37.59%	48.98%	★★★★☆☆

Click here to see the full list of 468 stocks from our Indian Undiscovered Gems With Strong Fundamentals screener.

Here's a peek at a few of the choices from the screener.

Akums Drugs and Pharmaceuticals (NSEI:AKUMS)

Simply Wall St Value Rating: ★★★★★☆

Overview: Akums Drugs and Pharmaceuticals Limited is engaged in the manufacturing and sale of pharmaceutical products and active pharmaceutical ingredients both in India and internationally, with a market capitalization of ₹143.83 billion.

Operations: Akums generates revenue primarily from its CDMO segment, contributing ₹36.32 billion, followed by branded and generic formulations at ₹6.76 billion, and APIs at ₹3.03 billion.

Akums Drugs and Pharmaceuticals, a promising player in the Indian pharmaceutical scene, reported a turnaround with net income of INR 601.71 million for Q1 2024, contrasting a net loss of INR 1.88 billion from the previous year. The firm has shown financial resilience with an EBIT covering interest payments by nearly ten times and maintaining satisfactory debt levels at a net debt to equity ratio of 40%. Recent strategic moves include an exclusive agreement with Triple Hair Inc., highlighting its focus on innovation and market expansion within India.

• Dive into the specifics of Akums Drugs and Pharmaceuticals here with our thorough health report.

• Explore historical data to track Akums Drugs and Pharmaceuticals' performance over time in our Past section.

IFB Industries (NSEI:IFBIND)

Simply Wall St Value Rating: ★★★★★☆

Overview: IFB Industries Limited, with a market cap of ₹92.43 billion, operates in the manufacturing and trading of home appliances both in India and internationally.

Operations: The primary revenue stream for IFB Industries comes from its Home Appliances segment, generating ₹36.32 billion, followed by the Engineering segment at ₹8.55 billion. The company also derives income from its Steel and Motor segments, contributing ₹1.65 billion and ₹0.67 billion, respectively.

IFB Industries, a notable player in the consumer durables sector, has shown impressive growth with earnings surging 612.7% over the past year, outpacing the industry average of 16.6%. The company boasts high-quality earnings and maintains a healthy financial position with cash exceeding total debt. Despite an increased debt-to-equity ratio from 11.6% to 22.9% over five years, its interest payments are well covered by EBIT at 7.5 times coverage. Recent quarterly results revealed sales of ₹12,691 million and net income of ₹375 million compared to a loss last year, highlighting strong operational performance amidst industry challenges.

• Unlock comprehensive insights into our analysis of IFB Industries stock in this health report.

• Learn about IFB Industries' historical performance.

Time Technoplast (NSEI:TIMETECHNO)

Simply Wall St Value Rating: ★★★★★★

Overview: Time Technoplast Limited is involved in the manufacture and sale of polymer and composite products both in India and internationally, with a market cap of ₹102.95 billion.

Operations: Time Technoplast generates revenue primarily from polymer products at ₹33.43 billion and composite products at ₹18 billion. The company's net profit margin exhibits a notable trend, reflecting its ability to manage costs effectively within these segments.

Time Technoplast, a nimble player in India's packaging sector, has shown impressive earnings growth of 44.6% over the past year, outpacing the industry's 8.7%. The company's net debt to equity ratio stands at a satisfactory 25.9%, indicating prudent financial management. With interest payments comfortably covered by EBIT at 5.7 times, Time Technoplast demonstrates robust fiscal health. Recent developments include winning a significant government contract worth INR 672 million and declaring an increased dividend of INR 2 per share for FY2024. These factors suggest strong operational momentum and strategic positioning within its industry niche.

• Click to explore a detailed breakdown of our findings in Time Technoplast's health report.

• Gain insights into Time Technoplast's historical performance by reviewing our past performance report.

Summing It All Up

• Unlock our comprehensive list of 468 Indian Undiscovered Gems With Strong Fundamentals by clicking here.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com